

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-19. (Canceled).

20. (Currently amended) A method of screening for a compound for treating or preventing breast cancer, said method comprising the steps of:

- a) contacting a test compound with a polypeptide encoded by a polynucleotide of the gene of BRC No. 456 selected from the group consisting of the genes of BRC Nos. 123-169, 171-449, and 451-512;
- b) detecting the binding activity between the polypeptide and the test compound; and
- c) selecting the test compound that binds to the polypeptide.

21-22. (Canceled).

23. (Currently amended) A method of screening for a compound for treating or preventing breast cancer, said method comprising the steps of:

- a) contacting a test compound with a polypeptide encoded by a polynucleotide of the gene of BRC No. 456 selected from the group consisting of the genes of BRC Nos. 123-169, 171-449, and 451-512;
- b) detecting the kinase biological activity of the polypeptide of step (a); ~~and~~
- c) selecting the test compound that suppresses the kinase biological activity of the polypeptide encoded by the polynucleotide of the gene of BRC NO. 456 selected from the group consisting of the genes of BRC Nos. 123-169, 171-175, 374-398, 448-449, and 451-471 as compared to the kinase biological activity of said polypeptide detected in the absence of the test compound; and
- d) further selecting from the test compound selected in step (c), the test compound that suppresses cell growth as compared to cell growth, or enhances the

~~biological activity of the polypeptide encoded by the polynucleotide selected from the group consisting of the genes of BRC Nos. 176-373, 399-447, and 472-512 as compared to the biological activity of said polypeptide detected in the absence of the test compound,~~

wherein said test compound is useful for treating or preventing breast cancer.

24. (Canceled).

25. (Currently amended) The method of claim 20, wherein said breast cancer is IDC, said method comprises the steps of:

- a) contacting a test compound with a polypeptide encoded by a polynucleotide of the gene of BRC No. 456 selected from the group consisting of the genes of BRC Nos. 448-449 and 451-512;
- b) detecting the binding activity between the polypeptide and the test compound; and
- c) selecting the test compound that binds to the polypeptide.

26-27. (Canceled).

28. (Currently amended) The method of claim 23, wherein said breast cancer is IDC and said method comprises the steps of:

- a) contacting a test compound with a polypeptide encoded by a polynucleotide of the gene of BRC No. 456 selected from the group consisting of the genes of BRC Nos. 448-449 and 451-512;
- b) detecting the kinase biological activity of the polypeptide of step (a); and
- c) selecting the test compound that suppresses the kinase biological activity of the polypeptide encoded by the polynucleotide of the gene of BRC No. 456 selected from the group consisting of the genes of BRC Nos. 448-449 and 451-471, as compared to the kinase biological activity of said polypeptide detected in the absence of the test compound; and

d) further selecting, from the test compound selected in step (c), the test compound that suppresses cell growth as compared to cell growth, or enhances the biological activity of the polypeptide encoded by the polynucleotide selected from the group consisting of the genes of BRC Nos. 472-512 as compared to the biological activity of said polypeptide detected in the absence of the test compound,
wherein said test compound is useful for treating or preventing IDC.

29-97. (Canceled).

98. (New) The method of claim 20, further comprising the step of:

(d) further selecting, from the test compound selected in step (c), the test compound that suppresses cell growth as compared to cell growth detected in the absence of the test compound.

99. (New) The method of claim 25, further comprising the step of:

(d) further selecting, from the test compound selected in step (c), the test compound that suppresses cell growth as compared to cell growth detected in the absence of the test compound.